ArticleFrontiers in pediatrics2021
Cardiovascular Disease Risk in Children With Chronic Kidney Disease: Impact of Apolipoprotein C-II and Apolipoprotein C-III.
Article in Frontiers in pediatrics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 10 citations in OpenAlex.
- Ambulatory arterial stiffness index: a window into early vascular ageing in childhood chronic kidney disease.Pediatric nephrology (Berlin, Germany) · 2026Article
- Clinical Relevance and Utility of Serum APOC2 Levels in Patients with Type 2 Diabetes Mellitus: A Comparative Study on Subjects with and without Pyogenic Liver Abscess.Hepatic medicine : evidence and research · 2026Article
- Pediatric Chronic Kidney Disease: Mind the Gap Between Reality and Expectations.Children (Basel, Switzerland) · 2025Review
- Plasma Calmodulin as a Biomarker of Subclinical Cardiovascular Disease in Pediatric Chronic Kidney Disease.Children (Basel, Switzerland) · 2025Article
- Lactoferrin in Pediatric Chronic Kidney Disease and Its Relationship with Cardiovascular Risk.Children (Basel, Switzerland) · 2024Article
- Plasma and Urinary Platelet Factor 4 as Biomarkers for Cardiovascular Risk in Children with Chronic Kidney Disease.Biomedicines · 2023Article
- Pregnancy Zone Protein as an Emerging Biomarker for Cardiovascular Risk in Pediatric Chronic Kidney Disease.Journal of clinical medicine · 2023Article
- Lipid Biomarkers and Atherosclerosis-Old and New in Cardiovascular Risk in Childhood.International journal of molecular sciences · 2023Review
- Non-linear relationship between sleep duration and blood pressure in children with short stature.Frontiers in pediatrics · 2023Article
- Cardiovascular Risks of Hypertension: Lessons from Children with Chronic Kidney Disease.Children (Basel, Switzerland) · 2022Review
- Complement Factor H and Related Proteins as Markers of Cardiovascular Risk in Pediatric Chronic Kidney Disease.Biomedicines · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease (CVD) is an evolving process that begins in the early stages of chronic kidney disease (CKD) in children. Several surrogate markers, such as ambulatory blood pressure monitoring (ABPM), left ventricular (LV) mass, and arterial stiffness assessment, allow for the early detection of subclinical CVD in pediatric CKD. Four groups of plasma samples (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.